
Benzinga Pro data, RAPT Therapeutics (NASDAQ:RAPT) reported Q1 sales of $641.00 thousand. Earnings fell to a loss of $20.47 million, resulting in a 14.16% decrease from last quarter. In Q4, RAPT Therapeutics brought in $756.00 thousand in sales but lost $17.93 million in earnings.